• In November 2023, a significant development occurred in the ophthalmic device industry as J&J Surgical Vision, Inc. and Alcon, Inc. successfully reached a settlement agreement, bringing an end to their ongoing legal battle. The dispute centered around femtosecond laser-assisted cataract surgery devices, a crucial segment within advanced cataract treatment technologies. This resolution marks a pivotal moment for both companies, allowing them to move forward without the distractions of prolonged litigation. The agreement not only eliminates legal uncertainties but also reinforces their focus on technological innovation and competitive market participation. As leading players in the ophthalmology sector, the resolution may pave the way for renewed investments and advancements in laser-assisted cataract surgery solutions, benefiting both providers and patients.

• In August 2023, Glaukos Corporation achieved a key regulatory milestone with the FDA 510(k) clearance of its innovative product, iStent Infinite. This device is specifically designed for standalone use in reducing elevated intraocular pressure (IOP) in patients diagnosed with primary open-angle glaucoma—one of the most common and progressive forms of glaucoma. The clearance underscores the company’s commitment to advancing minimally invasive glaucoma treatment options, offering a solution that can help preserve vision while minimizing surgical burden. The iStent Infinite represents a next-generation advancement in glaucoma therapy, empowering ophthalmologists with more flexibility and efficacy in managing challenging cases of uncontrolled IOP.

• In November 2022, Alcon, Inc. strategically expanded its presence in the glaucoma treatment landscape through the acquisition of Ivantis, Inc. This move significantly strengthens Alcon’s capabilities in the development, manufacturing, and commercialization of advanced minimally invasive glaucoma surgery (MIGS) devices. By integrating Ivantis’ innovative technologies, Alcon aims to accelerate product innovation and broaden its solutions for managing glaucoma more effectively. The acquisition also reflects Alcon’s ongoing commitment to enhancing ophthalmic care through precision-driven, less invasive surgical options that improve patient outcomes.

In this report, the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market has been segmented by Surgery, Target, Product, End User, and Geography.

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, Segmentation by Surgery

The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market has been segmented by Surgery into Glaucoma in Conjunction with Cataract and Stand Alone Glaucoma.

Glaucoma in Conjunction with Cataract
This sub-segment dominates the MIGS devices market due to the increasing preference for combining cataract and glaucoma procedures, which enhances surgical efficiency and patient outcomes. Over 65% of MIGS procedures globally are performed alongside cataract surgeries, driven by reduced recovery times and improved intraocular pressure (IOP) management. The dual approach offers a cost-effective solution for aging populations with coexisting ocular conditions.

Stand Alone Glaucoma
The stand-alone glaucoma surgery segment is gaining traction, accounting for nearly 35% of the MIGS market. This growth is propelled by rising awareness of early-stage glaucoma treatment and advancements in device technology. Stand-alone MIGS procedures are often preferred for patients not requiring cataract surgery, offering minimally invasive options with fewer complications and faster recovery.

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, Segmentation by Target

The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market has been segmented by Target into Trabecular Meshwork, Suprachoroidal Space, and Others.

Trabecular Meshwork
The trabecular meshwork segment leads the MIGS market, making up nearly 60% of all procedures. Devices targeting this pathway are preferred for their ability to enhance aqueous humor drainage via Schlemm’s canal, especially in cases of mild-to-moderate open-angle glaucoma. Their high success rate, minimal invasiveness, and compatibility with cataract surgeries contribute to their widespread clinical use.

Suprachoroidal Space
Representing approximately 25% of the MIGS market, devices targeting the suprachoroidal space aim to facilitate uveoscleral outflow, offering an alternative for more complex cases. Although some regulatory setbacks have slowed progress, newer technologies are renewing interest in this segment due to their promise in achieving significant IOP reduction.

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, Segmentation by Product

The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market has been segmented by Product into MIGS Stents, MIGS Shunts, and Others.

MIGS Stents
MIGS stents hold the largest share in the MIGS product landscape, contributing around 55% of the total market. These devices work by facilitating aqueous humor outflow via the trabecular meshwork or Schlemm’s canal, offering a minimally invasive and safe approach for managing glaucoma. Their proven effectiveness and compatibility with cataract surgeries have solidified their popularity among ophthalmic surgeons worldwide.

MIGS Shunts
Capturing approximately 30% of the global market, MIGS shunts provide an alternative drainage route for patients requiring more aggressive intraocular pressure (IOP) control. These devices are especially beneficial in moderate-to-severe glaucoma cases, and their growing use reflects advancements in targeted fluid redirection technologies.

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, Segmentation by End User

The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market has been segmented by End User into Eye Hospitals, Ophthalmology Clinics, and Outpatient Surgical Centers.

Eye Hospitals
Eye hospitals dominate the MIGS devices market, accounting for nearly 50% of usage worldwide. These facilities are equipped with specialized ophthalmic infrastructure, offering access to experienced glaucoma surgeons and advanced diagnostic tools. Their ability to deliver integrated care—from pre-op to follow-up—makes them the preferred choice for high-volume MIGS procedures.

Ophthalmology Clinics
With an estimated 30% share, ophthalmology clinics serve as key contributors to the growing adoption of minimally invasive glaucoma surgery. Known for personalized care and streamlined patient flow, these clinics are well-suited for treating patients with early to moderate-stage glaucoma, especially as outpatient procedures become more common.

Outpatient Surgical Centers
Making up around 20% of the end user market, outpatient surgical centers are emerging as cost-effective alternatives for glaucoma management. These centers specialize in same-day surgical care, attracting patients who prefer efficient, low-risk interventions. Their expanding presence in metro and tier-2 cities supports broader access to MIGS.

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, Segmentation by Geography

In this report, the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Share (%), by Geographical Region, 2024

North America
North America commands the largest share of the MIGS devices market, contributing around 40% globally. The region’s dominance is fueled by a combination of advanced medical infrastructure, a high incidence of glaucoma, and early adoption of innovative ophthalmic procedures, particularly in the United States.

Europe
Holding approximately 25% of the global market, Europe continues to show robust growth in MIGS adoption. This is attributed to favorable reimbursement frameworks, growing awareness of early glaucoma management, and increased availability of minimally invasive surgical options across the continent.

Asia Pacific
Asia Pacific captures nearly 20% of the market and is poised for the highest growth rate in the coming years. Rapid urbanization, aging populations, and enhanced access to eye care services are accelerating demand for MIGS technologies across countries like India, China, and Japan.

Middle East and Africa
With a market share of about 8%, the Middle East and Africa region is progressing steadily in MIGS adoption. Ongoing improvements in healthcare infrastructure, supported by both government and private investment, are creating opportunities for broader access to glaucoma treatment.

Latin America
Latin America contributes approximately 7% to the MIGS market. Rising awareness among healthcare professionals, combined with gradual modernization of medical facilities, is helping to expand the use of minimally invasive glaucoma surgeries in countries like Brazil and Mexico.

This report provides an in depth analysis of various factors that impact the dynamics of Minimally Invasive Glaucoma Surgery (MIGS) Devices Market. These factors include; Market Drivers, Restraints, and Opportunities.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Rising glaucoma prevalence
• Demand surge for minimally invasive surgeries
• Aging population's susceptibility

• Increased glaucoma awareness - Growing awareness of glaucoma and its long-term impact on vision is playing a critical role in driving the adoption of minimally invasive glaucoma surgery (MIGS) devices. Public health initiatives, advocacy from eye care professionals, and increased media coverage have contributed to better understanding of the condition’s progression and the importance of early intervention. As a result, more individuals are undergoing regular eye screenings and are being diagnosed at earlier stages, prompting interest in safer, less invasive surgical options like MIGS.

  Because glaucoma often advances without noticeable symptoms in its early stages, patients are now more conscious of the need for routine intraocular pressure (IOP) checks, especially those over the age of 60 or with a family history of the disease. This shift in patient behavior is strengthening the demand for procedures that not only manage the condition effectively but also minimize recovery time and surgical risks. MIGS procedures fulfill these needs, offering a reliable treatment path for patients with mild to moderate glaucoma who wish to avoid traditional, more invasive surgeries.

  With improved patient outcomes and growing clinical trust, MIGS devices are being recommended more frequently by ophthalmologists. Professional treatment guidelines and peer-reviewed research increasingly recognize MIGS as a valuable solution, contributing to its wider acceptance. As more patients learn about these benefits directly from healthcare providers or through positive word-of-mouth, confidence in these devices continues to grow, further accelerating market demand.

  Digital health platforms and online eye care resources are also playing a significant role in raising awareness. With easy access to information about glaucoma symptoms, treatment technologies, and surgical options, patients are more empowered to make informed decisions about their care. This heightened awareness and proactive attitude toward managing eye health is directly supporting the growth of MIGS devices, especially among populations seeking effective yet minimally disruptive treatment options.

Restraints:

• Surgeon training scarcity
• Regulatory hurdles for device approval
• Efficacy and safety concerns

• Traditional treatment reluctance - The continued preference for conventional glaucoma treatments remains a notable restraint in the growth of the minimally invasive glaucoma surgery (MIGS) devices market. Traditional methods such as eye drops, laser procedures, and standard surgical techniques like trabeculectomy have long been the mainstay in managing glaucoma. Many ophthalmologists, particularly those accustomed to these established practices, often hesitate to shift toward newer alternatives. This reliance on familiar procedures limits the integration of MIGS devices, despite their clinical benefits in early-stage and moderate cases.

  Patients also contribute to this reluctance, often opting for non-surgical treatment paths due to fear of surgery or a lack of awareness about MIGS options. Older adults, who form the largest demographic affected by glaucoma, may be especially cautious, preferring to avoid procedures even if they are minimally invasive. Additionally, concerns related to the affordability of MIGS devices and inconsistent insurance or reimbursement policies in some healthcare systems create further barriers to acceptance and accessibility.

  Another challenge lies in the perception of variable outcomes associated with MIGS. While these devices have shown significant promise, they are typically indicated for mild to moderate glaucoma and are not always suitable for advanced stages. This limited scope leads some clinicians to question their long-term efficacy compared to traditional surgeries, which are still regarded as more reliable for severe disease progression. As a result, MIGS is often viewed as a secondary option rather than a primary treatment approach.

  The lack of extensive long-term clinical data also affects broader adoption. Although research supporting the safety and effectiveness of MIGS continues to grow, some medical professionals and decision-makers remain cautious until more robust comparative studies are available. This conservative stance, driven by the need for stronger evidence and clearer cost-benefit validation, continues to hinder the widespread implementation of MIGS devices across global clinical practices.

Opportunities:

• Integrated treatment protocols
• Value-based care adoption
• Patient education initiatives

• Post-market surveillance enhancement - The evolution of post-market surveillance is creating new growth opportunities for minimally invasive glaucoma surgery (MIGS) devices. With increasing regulatory focus on long-term patient outcomes and device safety, manufacturers and healthcare providers are investing in more comprehensive monitoring systems. These frameworks help collect real-world data on device performance, offering insights that build confidence among clinicians and support broader acceptance of MIGS technologies in glaucoma management.

  One of the longstanding challenges in this market has been the limited availability of long-term performance data. Improved post-market surveillance addresses this gap by tracking outcomes such as intraocular pressure (IOP) control, device longevity, and patient satisfaction beyond the initial clinical trial period. These data points are vital for demonstrating the sustained efficacy and safety of MIGS procedures, especially to practitioners who are hesitant to move away from conventional surgical methods.

  Beyond clinical validation, enhanced surveillance enables a feedback loop for continuous product refinement. By analyzing real-world usage patterns and complication rates, manufacturers can make informed adjustments to device design and functionality. This ongoing improvement process helps deliver more reliable, user-friendly products that meet both regulatory standards and patient needs, while also enhancing competitiveness in a fast-evolving ophthalmic device landscape.

  Furthermore, robust post-market monitoring can inform better training programs for surgeons, promote evidence-based guidelines, and support favorable reimbursement decisions. As more high-quality data becomes accessible, it strengthens the case for MIGS inclusion in standardized glaucoma care protocols. This growing transparency and accountability are instrumental in fostering trust among stakeholders and accelerating the market penetration of MIGS devices worldwide.

Key players in Minimally Invasive Glaucoma Surgery (MIGS) Devices Market include,

• Alcon Inc.
• Allergan (a part of AbbVie Inc.)
• Glaukos Corporation
• Ivantis Inc.
• New World Medical Inc.
• Ellex Medical Lasers Ltd. (part of Lumibird Group)
• Santen Pharmaceutical Co. Ltd.
• Johnson & Johnson Vision (a subsidiary of Johnson & Johnson)
• Sight Sciences Inc.
• MicroSurgical Technology (MST)
• iStar Medical SA
• Nova Eye Medical Limited
• MediWorks Precision Instruments
• Carl Zeiss Meditec AG
• NeoMedix Corporation

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis